Related Experiment Videos
Recombinant human erythropoietin (rh-Epo) administration to normal child bone marrow donors
A M Martínez1, A Sastre, A Muñoz
1Department of Pediatric Hematology, La Paz Children's Hospital, Madrid, Spain.
Insights
Recombinant human erythropoietin (rh-Epo) effectively boosted hematocrit in young bone marrow donors, avoiding the need for transfusions. This treatment showed no adverse effects in children under 30 kg, making it a safe option for these donors.
Area of Science:
- Hematology
- Pediatric Medicine
- Transfusion Medicine
Background:
- Bone marrow donation in pediatric patients can lead to decreased hematocrit levels.
- Transfusions are often required to manage anemia post-donation.
- Identifying safe and effective interventions to support young donors is crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of recombinant human erythropoietin (rh-Epo) in healthy, low-weight pediatric bone marrow donors.
- To determine if rh-Epo administration can prevent the need for blood transfusions in this population.
- To assess the impact of rh-Epo on hematocrit levels before and after bone marrow harvesting.
Main Methods:
- 11 healthy bone marrow donors (<30 kg) received daily rh-Epo (100 units/kg) and iron supplementation for 3 weeks pre-harvest.
- 6 pediatric patients with low hematocrit post-harvest received rh-Epo (150 units/kg thrice weekly) and iron for 2 weeks.
- Hematocrit levels were monitored before and after bone marrow harvesting.
Main Results:
- Pre-harvest hematocrit increased significantly (mean 10.6% above baseline, P=0.0001) in donors receiving rh-Epo.
- Post-harvest, hematocrit decreased but returned to baseline or higher in most patients by day 15.
- No patients required blood transfusions during or after the bone marrow harvest procedure.
- No adverse side-effects related to rh-Epo administration were observed.
Conclusions:
- rh-Epo, combined with iron supplementation, is an effective strategy to increase hematocrit in low-weight pediatric bone marrow donors.
- This therapeutic approach can successfully avoid the need for blood transfusions in pediatric bone marrow donors.
- rh-Epo demonstrates a favorable safety profile in children undergoing bone marrow donation.
Abstract:
We have evaluated the efficacy of administering recombinant human erythropoietin (rh-Epo) to 11 healthy bone marrow donors weighing less than 30 kg. Three weeks before harvesting, the donors received 100 units/kg/day rh-Epo subcutaneously and oral iron supplementation (2.5 mg/kg twice daily). Six children with hematocrit values below the normal ranges for their ages after bone marrow harvesting received 150 units/kg rh-Epo three times a week for 2 weeks and oral iron supplementation at the same dose. No rh-Epo side-effects were observed. Hematocrit values before harvesting increased to between 5.7 and 18.5 (mean 10.6 +/- 1.2) above the baseline values (P = 0.0001). Hematocrit after harvesting decreased to between 4 and 19.5% (mean, 11.1) below the day 0 pre-harvest values. On day + 15 all but one patient had a hematocrit value > or = baseline value. No patient required transfusion during or after bone marrow harvest. Our results show that rh-Epo administration can avoid transfusion and has no side-effects in low weight child bone marrow donors.